@article{TCR31067,
author = {Shigeru Tanzawa and Masashi Ishihara and Terunobu Haruyama and Ryosuke Ochiai and Takahiko Sakamoto and Takeshi Honda and Shuji Ota and Yasuko Ichikawa and Kiyotaka Watanabe and Nobuhiko Seki},
title = {Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?},
journal = {Translational Cancer Research},
volume = {8},
number = {6},
year = {2019},
keywords = {},
abstract = {Currently, three strategies for primary treatment of advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations are being investigated: epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) monotherapy, EGFR-TKI + vascular endothelial growth factor (VEGF) inhibitor combination, and EGFR-TKI + cytotoxic anticancer agent combination (Tables 1,2).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/31067}
}